Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
about
Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and ValnemulinIn vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureusTherapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationThe changing face of antibiotic prescribing: the mutant selection window.A drug-eluting contact lensMutant selection window hypothesis updated.Emergence and spread of antibiotic resistance following exposure to antibiotics.Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis.Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia.Mutant prevention concentrations of four carbapenems against gram-negative rods.Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureusMutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Low correlation between MIC and mutant prevention concentration.In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
P2860
Q28468397-CF950196-9A7A-4FBF-84B6-1792D8BAA476Q34108501-00439D23-1FE8-4C3A-B197-6833B0965647Q34932274-5132C3DA-8D70-43B2-BB9D-C3B9DF841F3CQ35164756-DB7596AB-1E6E-4F5A-972B-6CE5583709D9Q35644095-6BB55539-C67B-4D84-932D-EFD425EB7262Q35875929-2889FCDB-C3C7-4FEA-8384-1370196A161EQ36311472-4A87B928-046D-46A3-8CB9-BB2341D08668Q36728061-161D961B-53C5-4CF0-B596-41251950A074Q37896674-40D09F09-0A7A-4EA2-9513-51B1D125313DQ40091678-75215A64-AA1A-4700-A1EF-3BA32160234EQ40342256-9A8077AC-F2D6-4FE6-A1F8-18A9AF36B3C9Q40749260-A898C603-2831-405D-B83E-86CAE9BE5AFAQ42127654-F8031F8F-787A-4A15-8438-A1BE2FBA9188Q42249678-E3AD96CD-8B6D-4D5A-BB40-C19DEB02040EQ42624603-75C18591-3951-4C06-8507-EEDECBF776F3Q42708766-03BC87B5-431B-4AD9-982D-296144F47DEDQ42943040-D8872C3F-25FD-4CF7-BCE8-AA19CB271DC3Q46315012-26D39008-2B3B-400F-9BC1-552E3BAAEBC0Q51703562-CCF86BD8-8F14-41A8-AD82-4425B245AA0A
P2860
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Mutant prevention concentratio ...... sistant Staphylococcus aureus.
@en
Mutant prevention concentration of garenoxacin
@nl
type
label
Mutant prevention concentratio ...... sistant Staphylococcus aureus.
@en
Mutant prevention concentration of garenoxacin
@nl
prefLabel
Mutant prevention concentratio ...... sistant Staphylococcus aureus.
@en
Mutant prevention concentration of garenoxacin
@nl
P2093
P2860
P1476
Mutant prevention concentratio ...... esistant Staphylococcus aureus
@en
P2093
Barry Kreiswirth
Karl Drlica
Nathan Perl-Rosenthal
William Eisner
P2860
P304
P356
10.1128/AAC.47.3.1023-1027.2003
P407
P50
P577
2003-03-01T00:00:00Z